← Back to search

Protein Structures and Oligomeric States

Enter a protein name, UniProt accession or PDB ID. Name searches ask you to confirm the protein identity before related structures are queried.

Current Protein Identity：P28062 New Search
22PDB entries
22Biological assembly
44chain/assembly records
Main Difference Dimensions in This Set
Different construct Different assembly state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics

Difference tags compare only the current result set; every original PDB and assembly record remains separate.

Related-Structure Differences

Each row represents one biological assembly in one PDB entry; multiple monomers of the same protein are listed separately.

PDB Entry Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Experimental Method Experimental Conditions Structure Quality
5L5A Yeast 20S proteasome with human beta5i (1-138; R57T) Deposited 2016-05-28 Assembly 1 Insufficient information Heteromer；Protein × 28 PDB declaration: 28-meric（28） Consistent with protein count
Chain K 73–210（138 aa）
Chain Y 73–210（138 aa）
Not recorded MG MAGNESIUM ION × 10 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；20 mM MgAC2, 13% MPD, 0.1 M MES
Resolution 2.40 Å R-free 0.219
5L5B Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) Deposited 2016-05-28 Assembly 1 Insufficient information Heteromer；Protein × 28 PDB declaration: 28-meric（28） Consistent with protein count
Chain K 73–210（138 aa）
Chain Y 73–210（138 aa）
Not recorded MG MAGNESIUM ION × 9 CL CHLORIDE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；20 mM MgAC2, 13% MPD, 0.1 M MES
Resolution 2.80 Å R-free 0.211
5L5D Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with ONX 0914 Deposited 2016-05-28 Assembly 1 Insufficient information Heteromer；Protein × 28 PDB declaration: 28-meric（28） Consistent with protein count
Chain K 73–210（138 aa）
Chain Y 73–210（138 aa）
Not recorded MG MAGNESIUM ION × 8 CL CHLORIDE ION × 2 04C 1,2,4-trideoxy-4-methyl-2-{[N-(morpholin-4-ylacetyl)-L-alanyl-O-methyl-L-tyrosyl]amino}-1-phenyl-D-xylitol × 6 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；20 mM MgAC2, 13% MPD, 0.1 M MES
Resolution 2.80 Å R-free 0.221
5L5E Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with carfilzomib Deposited 2016-05-28 Assembly 1 Insufficient information Heteromer；Protein × 28 PDB declaration: 28-meric（28） Consistent with protein count
Chain K 73–210（138 aa）
Chain Y 73–210（138 aa）
Not recorded MG MAGNESIUM ION × 7 CL CHLORIDE ION × 4 3BV N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-[(2R,3S,4S)-1,3-dihydroxy-2,6-dimethylheptan-4-yl]-L-phenylalaninamide × 6 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；20 mM MgAC2, 13% MPD, 0.1 M MES
Resolution 2.90 Å R-free 0.227
5L5F Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with bortezomib Deposited 2016-05-28 Assembly 1 Insufficient information Heteromer；Protein × 28 PDB declaration: 28-meric（28） Consistent with protein count
Chain K 73–210（138 aa）
Chain Y 73–210（138 aa）
Not recorded MG MAGNESIUM ION × 8 CL CHLORIDE ION × 4 BO2 N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；20 mM MgAC2, 13% MPD, 0.1 M MES
Resolution 2.50 Å R-free 0.228
5L5H Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with PR-924 Deposited 2016-05-28 Assembly 1 Insufficient information Heteromer；Protein × 28 PDB declaration: 28-meric（28） Consistent with protein count
Chain K 73–210（138 aa）
Chain Y 73–210（138 aa）
Not recorded MG MAGNESIUM ION × 9 CL CHLORIDE ION × 2 39V N-[(3-methyl-1H-inden-2-yl)carbonyl]-D-alanyl-N-[(2S,4R)-5-hydroxy-4-methyl-3-oxo-1-phenylpentan-2-yl]-L-tryptophanamide × 2 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；20 mM MgAC2, 13% MPD, 0.1 M MES
Resolution 2.60 Å R-free 0.216
5L5I Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 9 Deposited 2016-05-28 Assembly 1 Insufficient information Heteromer；Protein × 28 PDB declaration: 28-meric（28） Consistent with protein count
Chain K 73–210（138 aa）
Chain Y 73–210（138 aa）
Not recorded MG MAGNESIUM ION × 8 CL CHLORIDE ION × 2 38X N-[(3-methyl-1H-inden-2-yl)carbonyl]-D-alanyl-N-[(2S,4R)-1-cyclohexyl-5-hydroxy-4-methyl-3-oxopentan-2-yl]-L-tryptophanamide × 2 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；20 mM MgAC2, 13% MPD, 0.1 M MES
Resolution 2.90 Å R-free 0.210
5L5J Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 14 Deposited 2016-05-28 Assembly 1 Insufficient information Heteromer；Protein × 28 PDB declaration: 28-meric（28） Consistent with protein count
Chain K 73–210（138 aa）
Chain Y 73–210（138 aa）
Not recorded MG MAGNESIUM ION × 8 CL CHLORIDE ION × 2 6N5 ~{N}-[(2~{S})-1-[[(2~{S})-3-(4-methoxyphenyl)-1-[[(2~{S},3~{S},4~{R})-4-methyl-3,5-bis(oxidanyl)-1-phenyl-pentan-2-yl]amino]-1-oxidanylidene-propan-2-yl]amino]-1-oxidanylidene-propan-2-yl]-1-methyl-5~{H}-indene-2-carboxamide × 4 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；20 mM MgAC2, 13% MPD, 0.1 M MES
Resolution 2.90 Å R-free 0.200
5L5O Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 16 Deposited 2016-05-28 Assembly 1 Insufficient information Heteromer；Protein × 28 PDB declaration: 28-meric（28） Consistent with protein count
Chain K 73–210（138 aa）
Chain Y 73–210（138 aa）
Not recorded MG MAGNESIUM ION × 8 CL CHLORIDE ION × 2 79P (2~{S})-3-(1~{H}-indol-3-yl)-~{N}-[(2~{S},3~{S},4~{R})-4-methyl-3,5-bis(oxidanyl)-1-phenyl-pentan-2-yl]-2-[[(2~{R})-2-(2-morpholin-4-ylethanoylamino)propanoyl]amino]propanamide × 4 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；20 mM MgAC2, 13% MPD, 0.1 M MES
Resolution 2.60 Å R-free 0.214
5L5P Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 17 Deposited 2016-05-28 Assembly 1 Insufficient information Heteromer；Protein × 28 PDB declaration: 28-meric（28） Consistent with protein count
Chain K 73–210（138 aa）
Chain Y 73–210（138 aa）
Not recorded MG MAGNESIUM ION × 9 CL CHLORIDE ION × 2 79L (2~{S})-3-(4-methoxyphenyl)-~{N}-[(2~{S},3~{S},4~{R})-4-methyl-3,5-bis(oxidanyl)-1-phenyl-pentan-2-yl]-2-[[(2~{R})-2-(2-morpholin-4-ylethanoylamino)propanoyl]amino]propanamide × 4 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；20 mM MgAC2, 13% MPD, 0.1 M MES
Resolution 2.80 Å R-free 0.207
5L5Q Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone 18 Deposited 2016-05-28 Assembly 1 Insufficient information Heteromer；Protein × 28 PDB declaration: 28-meric（28） Consistent with protein count
Chain K 73–210（138 aa）
Chain Y 73–210（138 aa）
Not recorded MG MAGNESIUM ION × 8 CL CHLORIDE ION × 2 6NV ~{N}-[(2~{R})-1-[[(2~{S})-3-(4-methoxyphenyl)-1-[[(2~{S},3~{S},4~{R})-4-methyl-3,5-bis(oxidanyl)-1-phenyl-pentan-2-yl]amino]-1-oxidanylidene-propan-2-yl]amino]-1-oxidanylidene-propan-2-yl]-1-methyl-5~{H}-indene-2-carboxamide × 2 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；20 mM MgAC2, 13% MPD, 0.1 M MES
Resolution 2.80 Å R-free 0.210
5L5R Yeast 20S proteasome with human beta5i (1-138;V31M) and human beta6 (97-111; 118-133) Deposited 2016-05-28 Assembly 1 Insufficient information Heteromer；Protein × 28 PDB declaration: 28-meric（28） Consistent with protein count
Chain K 73–210（138 aa）
Chain Y 73–210（138 aa）
Not recorded MG MAGNESIUM ION × 8 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；20 mM MgAC2, 13% MPD, 0.1 M MES
Resolution 2.90 Å R-free 0.221
5L5S Yeast 20S proteasome with human beta5i (1-138; V31M) and human beta6 (97-111; 118-133) in complex with PR-924 Deposited 2016-05-28 Assembly 1 Insufficient information Heteromer；Protein × 28 PDB declaration: 28-meric（28） Consistent with protein count
Chain K 73–210（138 aa）
Chain Y 73–210（138 aa）
Not recorded MG MAGNESIUM ION × 9 CL CHLORIDE ION × 2 39V N-[(3-methyl-1H-inden-2-yl)carbonyl]-D-alanyl-N-[(2S,4R)-5-hydroxy-4-methyl-3-oxo-1-phenylpentan-2-yl]-L-tryptophanamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；20 mM MgAC2, 13% MPD, 0.1 M MES
Resolution 2.60 Å R-free 0.211
5L5T Yeast 20S proteasome with human beta5i (1-138; V31M) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 16 Deposited 2016-05-28 Assembly 1 Insufficient information Heteromer；Protein × 28 PDB declaration: 28-meric（28） Consistent with protein count
Chain K 73–210（138 aa）
Chain Y 73–210（138 aa）
Not recorded MG MAGNESIUM ION × 8 CL CHLORIDE ION × 2 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 79P (2~{S})-3-(1~{H}-indol-3-yl)-~{N}-[(2~{S},3~{S},4~{R})-4-methyl-3,5-bis(oxidanyl)-1-phenyl-pentan-2-yl]-2-[[(2~{R})-2-(2-morpholin-4-ylethanoylamino)propanoyl]amino]propanamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；20 mM MgAC2, 13% MPD, 0.1 M MES
Resolution 2.90 Å R-free 0.195
5L5U Yeast 20S proteasome with human beta5i (1-138; V31M) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 17 Deposited 2016-05-28 Assembly 1 Insufficient information Heteromer；Protein × 28 PDB declaration: 28-meric（28） Consistent with protein count
Chain K 73–210（138 aa）
Chain Y 73–210（138 aa）
Not recorded MG MAGNESIUM ION × 11 CL CHLORIDE ION × 2 04C 1,2,4-trideoxy-4-methyl-2-{[N-(morpholin-4-ylacetyl)-L-alanyl-O-methyl-L-tyrosyl]amino}-1-phenyl-D-xylitol × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；20 mM MgAC2, 13% MPD, 0.1 M MES
Resolution 2.60 Å R-free 0.211
5L5V 'Yeast 20S proteasome with human beta5i (1-138; V31M) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 18 Deposited 2016-05-28 Assembly 1 Insufficient information Heteromer；Protein × 28 PDB declaration: 28-meric（28） Consistent with protein count
Chain K 73–210（138 aa）
Chain Y 73–210（138 aa）
Not recorded MG MAGNESIUM ION × 9 CL CHLORIDE ION × 2 6NV ~{N}-[(2~{R})-1-[[(2~{S})-3-(4-methoxyphenyl)-1-[[(2~{S},3~{S},4~{R})-4-methyl-3,5-bis(oxidanyl)-1-phenyl-pentan-2-yl]amino]-1-oxidanylidene-propan-2-yl]amino]-1-oxidanylidene-propan-2-yl]-1-methyl-5~{H}-indene-2-carboxamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；20 mM MgAC2, 13% MPD, 0.1 M MES
Resolution 2.70 Å R-free 0.208
5LTT Yeast 20S proteasome with human beta5i (1-138; R57T)in complex with PR-924 Deposited 2016-09-07 Assembly 1 Insufficient information Heteromer；Protein × 28 PDB declaration: 28-meric（28） Consistent with protein count
Chain K 73–210（138 aa）
Chain Y 73–210（138 aa）
Not recorded MG MAGNESIUM ION × 8 CL CHLORIDE ION × 2 39V N-[(3-methyl-1H-inden-2-yl)carbonyl]-D-alanyl-N-[(2S,4R)-5-hydroxy-4-methyl-3-oxo-1-phenylpentan-2-yl]-L-tryptophanamide × 2 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；20 mM MgAC2, 13% MPD, 0.1 M MES
Resolution 2.70 Å R-free 0.247
5M2B Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with thiazole based inhibitor Ro19 Deposited 2016-10-12 Assembly 1 Insufficient information Heteromer；Protein × 28 PDB declaration: 28-meric（28） Consistent with protein count
Chain K 73–210（138 aa）
Chain Y 73–210（138 aa）
Not recorded MG MAGNESIUM ION × 7 CL CHLORIDE ION × 4 7DX (2~{S})-2-cyclohexyl-4-oxidanylidene-4-[[7-(4-phenyl-1,3-thiazol-2-yl)quinolin-2-yl]amino]butanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；20 mM MgAC2, 13% MPD, 0.1 M MES
Resolution 2.70 Å R-free 0.218
6AVO Cryo-EM structure of human immunoproteasome with a novel noncompetitive inhibitor that selectively inhibits activated lymphocytes Deposited 2017-09-04 Assembly 1 Protein heterocomplex Heteromer；Protein × 28 PDB declaration: 28-meric（28） Consistent with protein count
Chain C 73–276（204 aa）
Chain D 73–276（204 aa）
Not recorded BZ7 N~1~-{2-[([1,1'-biphenyl]-3-carbonyl)amino]ethyl}-N~4~-tert-butyl-N~2~-(3-phenylpropanoyl)-L-aspartamide × 2 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.80 Å
6E5B Human Immunoproteasome 20S particle in complex with compound 1 Deposited 2018-07-19 Assembly 1 Protein heterocomplex Heteromer；Protein × 28 PDB declaration: 28-meric（28） Consistent with protein count
Chain K 1–276（276 aa）
Chain Y 1–276（276 aa）
Not recorded SCN THIOCYANATE ION × 3 NA SODIUM ION × 12 HUJ [(1R)-3-methyl-1-[[1-[2-[(2,3,4-trimethoxyphenyl)carbonylamino]ethyl]-1,2,3-triazol-4-yl]carbonylamino]butyl]-tris(oxidanyl)boron × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；39% (v/v) 2-methyl-2,4-pentanediol (MPD), 0.2M sodium thiocyanate
Resolution 2.77 Å R-free 0.291
7AWE HUMAN IMMUNOPROTEASOME 20S PARTICLE IN COMPLEX WITH [(1R)-2-(1-benzofuran-3-yl)-1-{[(1S,2R,4R)-7-oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid Deposited 2020-11-06 Assembly 1 Protein heterocomplex Heteromer；Protein × 28 PDB declaration: 28-meric（28） Consistent with protein count
Chain L 73–275（203 aa）
Chain Z 73–275（203 aa）
Not recorded NA SODIUM ION × 13 SCN THIOCYANATE ION × 11 S5K [(1R)-2-(1-benzofuran-3-yl)-1-{[(1S,2R,4R)-7-oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.6；291 K；42 % MPD, 0.20 M NaSCN
Resolution 2.29 Å R-free 0.214
7B12 HUMAN IMMUNOPROTEASOME 20S PARTICLE IN COMPLEX WITH [2-(3-ethylphenyl)-1-[(2S)-3-phenyl-2-[(pyrazin-2-yl)formamido]propanamido]ethyl]boronic acid Deposited 2020-11-23 Assembly 1 Protein heterocomplex Heteromer；Protein × 28 PDB declaration: 28-mer（28） Consistent with protein count
Chain L 73–275（203 aa）
Chain Z 73–275（203 aa）
Not recorded SO4 SULFATE ION × 5 NA SODIUM ION × 6 SKN ((R)-2-(3-ethylphenyl)-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)ethyl)boronic acid × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.6；291 K；42 % MPD, 0.20 M NaSCN,
Resolution 2.43 Å R-free 0.225

This page presents structural evidence recorded in PDB/mmCIF.“No recorded non-water small molecule” does not prove that the experimental sample was ligand-free; experimental conditions belong to the PDB experiment, while ligands and copy counts are shown for each biological assembly.